Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside its participation at the European Congress on Obesity and publication in The New England Journal of Medicine.